7 - 10 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Whole blood or Labcorp buccal swab kit (buccal swab collection kit contains 4 swabs and instructions for use of a buccal swab)
2 mL whole blood or one buccal swab kit (4 swabs)
1 mL whole blood or two buccal swabs
Lavender-top (EDTA) tube or yellow-top (ACD) tube or Labcorp buccal swab kit
Collect specimen in a lavender-top (EDTA) or yellow-top (ACD) tube, or use a buccal swab kit (4 swabs). Ship whole blood specimen at room temperature or frozen. Ship buccal swab kit at room temperature.
Maintain whole blood specimen at room temperature or refrigerated for 28 days or frozen for 2 years. Maintain buccal swabs at room temperature for 2 months.
Whole Blood: 28 days
Swabs: 2 Months
Whole Blood: 28 days
Whole Blood: 2 years
Hemolysis; quantity not sufficient for analysis; improper container; single buccal swab; wet buccal swab; buccal swabs without outer collection envelope; severely damaged buccal swab envelope; buccal swab envelope received open; frozen glass tube
Cytochrome P450 2D6 (CYP2D6) is a drug-metabolizing enzyme involved in the metabolism of more than 65 clinically important drugs including some antidepressants, anti-psychotics, opioids, beta-blockers, antiemetics, atomoxetine and tamoxifen. Individuals with some variant CYP2D6 alleles may experience a reduced therapeutic response and may be at risk for side effects from drugs that are metabolized by CYP2D6. CYP2D6 genotype information can be utilized to predict CYP2D6 metabolic phenotype, which can be used as an aid in determining a therapeutic strategy for drugs that are metabolized by CYP2D6. For example, CYP2D6 ultrarapid metabolizers may experience exaggerated side effects after the administration of codeine, while poor metabolizers may experience a reduced analgesic effect due to insufficient biotransformation into morphine. In these instances, alternative drugs may be considered.
Variation in the CYP2D6 gene can result in ultrarapid (UM), normal (NM), intermediate (IM) and poor (PM) drug-metabolizing phenotypes. Depending upon the genotype, a range between some of these phenotypes may be predicted by this assay. In general, relative to the *1 allele (normal function), *2, *35 and *53 alleles have normal function. *9, *10, *14, *17, *29, *41, *49 and *59 alleles have decreased function, while *3, *4, *5, *6, *7, *8, *11, *12, *13, *15, *31, *36, *40, *42 and *68 alleles have no function.
The exact effect of a particular genotype on individual drugs can vary. In addition to genotype, the metabolism of drugs may be influenced by additional factors that include environmental, dietary and other medications; these factors and others should be considered prior to initialing a new therapy. All results must be interpreted in the context of other test results and clinical findings. Results do not rule out the possibility of other variant alleles in CYP2D6 or other variant alleles in other drug metabolism pathways. Patients should speak with their healthcare provider about the individual results of this test.
Molecular-based testing is highly accurate, but as in any laboratory test, rare diagnostic errors may occur.
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
DNA analysis is performed by allele-specific real-time polymerase chain reactions (RT-PCR) to detect single-nucleotide polymorphisms (SNPs), insertions or deletions (indels), hybrid, hybrid tandem and copy number variants (CNVs) within CYP2D6 gene and to assign variant CYP2D6 *2, *3, *4, *5 (deletion), *6, *7, *8, *9, *11, *12, *13 (hybrid), *13, *15, *17, *29, *31, *35, *36 (hybrid), *36+*10 (hybrid tandem), *40, *41, *42, *49, *53, *59 and *68 (hybrid) alleles and gene duplications (DUPS; copy number (CN) designated). *1 denotes detection of the reference (wild-type) sequence at the assessed alleles. No other variants in this gene are detected by this assay.
Analysis for the *42 allele is dependent upon adequate DNA concentration.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|512150||Cytochrome P450 2D6 Genotyping||512202||2D6 Genotype:||40425-1|
|512150||Cytochrome P450 2D6 Genotyping||512203||2D6 Metabolic Activity:||79715-9|
|512150||Cytochrome P450 2D6 Genotyping||512204||Director Review:||72486-4|
|512150||Cytochrome P450 2D6 Genotyping||505763||Interpretation:||56850-1|
|512150||Cytochrome P450 2D6 Genotyping||505764||CYP2D6 Information:||62364-5|
|512150||Cytochrome P450 2D6 Genotyping||000000||MGRM Informed Consent Review||N/A|
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf